Company intends to increase sales in the UK to approximately 2 million Euros by focusing on seven molecules which are already registered in the country
Merck and Ridgeback will appeal the decision and request a re-examination of the CHMP’s opinion.
CHMP positive opinion is based on evidence from the EFFISAYIL trial, the largest clinical trial in
NULIBRY is a first-in-class cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A.
Companies concluded memorandum of understanding that Takeda will continue to provide distribution support for the Moderna COVID-19 vaccines for a transitional period
Moderna's updated COVID-19 mRNA vaccine will be available for the 2025-2026 vaccination season, pending a European Commission authorization decision
European Commission granted approval of darolutamide in combination with androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC)
Emcure Pharmaceuticals successfully completes USFDA PAI of Oncology facility
It is intended for contrast enhancement in MRI scans
SUP will obtain regulatory approvals for selling Tiotropium DPI in China
Subscribe To Our Newsletter & Stay Updated
